PPADS Tetrasodium is an non-selective purinergic antagonists of P2 ATP receptors. PPADS Tetrasodium is also a potential neuroprotective agents for the treatment of autoimmune and demyelinating disease.
P2X and P2Y purinergic receptors are ATP-sensitive receptors responsible for mediating a large variety of excitatory postsynaptic responses including fast transmission at central synapses, contraction of smooth muscle cells, platelet aggregation, macrophage activation, and apoptosis. PPADS is a non-selective P2 purinergic antagonist that blocks recombinant P2X1-5 (IC50s = 1-2.6 μM), native P2Y2-like (IC50 = ~0.9 mM), and recombinant P2Y4 (IC50 = ~15 mM) receptors. PPADS antagonism of ATP-sensitive P2 receptors produces neuroprotective effects in an ischemia model with permanent middle cerebral artery occlusion in spontaneously hypertensive rats.
ChEBI: Tetrasodium 5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate is an organic sodium salt that is the tetrasodium salt of 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid It has a role as a purinergic receptor P2X antagonist. It is an organic sodium salt and an organosulfonate salt. It contains a 5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate.
Non-selective P2 purinoceptor antagonist which blocks responses at both pre- and post-junctional sites.
